Article

White House Unveils Awaited Affordable Care Act Profit Margin Rule

A proposed federal rule to cap profit margins for certain health insurance plans and prescription drug benefit programs is now available for review.

The latest in a raft of rules required by President Obama’s landmark healthcare law, the proposed rule was drafted by the Centers for Medicare and Medicaid Services (CMS) and sent to Pennsylvania Avenue on Thursday.

Read the full story: http://bit.ly/XcbJL3

Source: The Hill

Related Videos
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Michelle Hessen, OD
Douglas Flora, MD, FACCC
Molly Dean, MSW, Siftwell
Dr Xin Hu
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
rachel rohaidy
Related Content
Pediatric AD. | Image Credit: Evgeniya Primavera - stock.adobe.com
March 13th 2025

Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care

Cameron Santoro
Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Sharon Hesterlee, PhD
March 13th 2025

Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025

Kyle Munz Sharon Hesterlee, PhD
Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Just 4 of the 20 cell and gene therapy trials in the study submitted the same trial evidence to both the FDA and EMA. | Image credit: Treecha - stock.adobe.com
March 13th 2025

Uniform Global Standards, Processes Could Accelerate CGT Approvals, Access

Rose McNulty
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
ART | Image credit: gamjai - stock.adobe.com
March 13th 2025

Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir

Julia Bonavitacola
The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo